CR20200487A - Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos - Google Patents

Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos

Info

Publication number
CR20200487A
CR20200487A CR20200487A CR20200487A CR20200487A CR 20200487 A CR20200487 A CR 20200487A CR 20200487 A CR20200487 A CR 20200487A CR 20200487 A CR20200487 A CR 20200487A CR 20200487 A CR20200487 A CR 20200487A
Authority
CR
Costa Rica
Prior art keywords
peptide
tyrosine
conjugates
glp
glucagon
Prior art date
Application number
CR20200487A
Other languages
English (en)
Inventor
Raul Camacho
Martin A Case
Mark J Wall
Yue-Mei Zhang
Ellen Chi
Suzanne Edavettal
Wilson Edwards
Songmao Zheng
Rui Zhang
Lisa Norquay
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20200487A publication Critical patent/CR20200487A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención comprende conjugados que comprenden un péptido de fusión péptido similar al glucagón 1 (GLP-1) acoplado a un péptido PYY cíclico. La invención también se relaciona con composiciones farmacéuticas y con métodos para usarlas. Los conjugados novedosos son útiles para prevenir, tratar o corregir enfermedades y trastornos descritos en la presente descripción.</p>
CR20200487A 2018-04-25 2019-04-24 Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos CR20200487A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662313P 2018-04-25 2018-04-25
US2018029284 2018-04-25
PCT/IB2019/053384 WO2019207505A1 (en) 2018-04-25 2019-04-24 Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CR20200487A true CR20200487A (es) 2021-03-11

Family

ID=66676857

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200487A CR20200487A (es) 2018-04-25 2019-04-24 Conjugados del pèptido de fusiòn pèptido similar al glucagòn 1 (glp-1) acoplado al pèptido tirosina tirosina cìclico y usos de estos

Country Status (26)

Country Link
EP (2) EP4640701A3 (es)
JP (2) JP7676148B2 (es)
KR (2) KR102865076B1 (es)
CN (2) CN112004822B (es)
AU (2) AU2019259790B2 (es)
BR (1) BR112020021562A2 (es)
CA (1) CA3096792A1 (es)
CL (1) CL2020002718A1 (es)
CO (1) CO2020013221A2 (es)
CR (1) CR20200487A (es)
DO (1) DOP2020000192A (es)
EC (1) ECSP20067968A (es)
ES (1) ES3049134T3 (es)
IL (2) IL319050A (es)
JO (1) JOP20200265A1 (es)
MA (1) MA52361A (es)
MX (2) MX2020011293A (es)
MY (1) MY207588A (es)
NI (1) NI202000071A (es)
PE (1) PE20211457A1 (es)
PH (1) PH12020551659A1 (es)
SA (1) SA520420401B1 (es)
SG (1) SG11202009844SA (es)
TW (1) TWI847981B (es)
UY (1) UY38200A (es)
WO (1) WO2019207505A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
CA3163507A1 (en) * 2019-12-04 2021-06-10 The Scripps Research Institute Peptide conjugates and methods of use
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN116478298A (zh) * 2021-12-31 2023-07-25 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN117327200B (zh) * 2023-11-28 2024-02-09 西宝生物科技（上海）股份有限公司 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法
WO2025247862A1 (en) * 2024-05-27 2025-12-04 Numaferm Gmbh Methods for the c-terminal modification of (poly)peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094652A1 (en) * 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
EA011860B1 (ru) * 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
BRPI0518761A2 (pt) * 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
AU2006279276A1 (en) * 2005-07-29 2007-02-15 Amprotein Corporation Chimeric therapeutic agents
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
WO2008021560A2 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
SG10201406063XA (en) * 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
EP4442314A2 (en) * 2015-10-28 2024-10-09 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y

Also Published As

Publication number Publication date
KR102865076B1 (ko) 2025-09-25
PH12020551659A1 (en) 2021-07-26
CN119708256A (zh) 2025-03-28
IL278197B1 (en) 2025-03-01
JP2021522258A (ja) 2021-08-30
UY38200A (es) 2019-10-31
DOP2020000192A (es) 2021-04-30
EP3784692C0 (en) 2025-08-27
SA520420401B1 (ar) 2023-01-26
AU2023274117B2 (en) 2025-04-10
CL2020002718A1 (es) 2021-01-29
PE20211457A1 (es) 2021-08-05
BR112020021562A2 (pt) 2021-03-02
JOP20200265A1 (ar) 2020-10-21
EP3784692A1 (en) 2021-03-03
IL278197B2 (en) 2025-07-01
JP7676148B2 (ja) 2025-05-14
AU2019259790B2 (en) 2023-08-31
AU2023274117A1 (en) 2023-12-21
CN112004822A (zh) 2020-11-27
ES3049134T3 (en) 2025-12-15
MA52361A (fr) 2021-03-03
IL278197A (en) 2020-11-30
TWI847981B (zh) 2024-07-11
MY207588A (en) 2025-03-05
AU2019259790A1 (en) 2020-10-22
EP4640701A3 (en) 2025-12-17
ECSP20067968A (es) 2020-11-30
CO2020013221A2 (es) 2020-11-10
JP2025118735A (ja) 2025-08-13
KR20210005674A (ko) 2021-01-14
CN112004822B (zh) 2025-01-14
MX2025014917A (es) 2026-02-03
EP4640701A2 (en) 2025-10-29
MX2020011293A (es) 2020-11-13
TW202014433A (zh) 2020-04-16
WO2019207505A1 (en) 2019-10-31
SG11202009844SA (en) 2020-11-27
EP3784692B1 (en) 2025-08-27
NI202000071A (es) 2021-01-21
KR20250142942A (ko) 2025-09-30
CA3096792A1 (en) 2019-10-31
IL319050A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
MX2020011293A (es) Conjugados del peptido de fusion peptido similar al glucagon 1 (glp-1) acoplado al peptido tirosina tirosina ciclico y usos de estos.
CL2019001466A1 (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico.
EA202192588A1 (ru) Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения
JOP20210089A1 (ar) نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها
MX2022007439A (es) Antagonistas de piperidina del receptor de melanocortina subtipo 2 (mc2r) sustituidos con gem y usos de los mismos.
JOP20190193A1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX393803B (es) Derivados de amida como bloqueadores de nav1.7 y nav1.8
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
EA202191280A1 (ru) Конструкции для доставки для трансцитоза и связанные способы
PH12021552477A1 (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CR20220206A (es) Agonistas del receptor npy2
AR104173A1 (es) Variantes de protoxina ii y métodos de uso
ZA202308388B (en) Nasal compositions comprising alcaftadine
JOP20230150A1 (ar) صيغ ببتيد علاجية
EA202092547A1 (ru) Связанные со слитым пептидом, содержащим глюкагонподобный пептид 1 (glp-1), циклические пептидные тирозинтирозиновые конъюгаты и их применение
JOP20230210A1 (ar) أشكال بلورية من (4s)-42-كلورو-4-إثيل-37-فلورو-53-مثوكسي-23، 5-ديوكسو-41-(ثلاثي فلورومثيل)-23h-6-آزا-3 (4، 1) بيريدينا-1 (1)- تريازولو-2 (1، 2)، 7 (1) ثنائي بنزيناهبتافان-47-كربوكساميد
MX2022006743A (es) Formulaciones liquidas estables de peptido 1 similar al glucagon o analogos del mismo.
EA201991047A1 (ru) Связанные с антителами циклические пептидные тирозин-тирозиновые соединения в качестве модуляторов рецепторов нейропептида y
UA122320U (uk) Протизапальний засіб для лікування захворювань суглобів і хребта &#34;диклофенак-віола&#34;